NCT01202825: TMC647055HPC1001 - First-in-human Trial to Examine Safety, Tolerability and Pharmacokinetics (How the Drug is Absorbed Into the Bloodstream) of Increasing Single Oral Doses and of Increasing Repeated Oral Doses of TMC647055 in Healthy Volunteers and in Hepatitis C Virus Infected Patients |
|
|
| Completed | 1 | 72 | Europe | TMC647055, Placebo, TMC435 | Tibotec Pharmaceuticals, Ireland | Hepatitis C | 11/11 | 11/11 | | |